Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out – Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense

New York, USA, July 19, 2023 (GLOBE NEWSWIRE) — Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out – Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense

The dynamics of the amyotrophic lateral sclerosis market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expected launch of emerging therapies during the forecasted period of 2023–2032.

DelveInsight’s Amyotrophic Lateral Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, amyotrophic lateral sclerosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Amyotrophic Lateral Sclerosis Market Report

• As per DelveInsight’s analysis, the amyotrophic lateral sclerosis market size in the 7MM was approximately USD 500 million in 2022.
• According to the assessment done by DelveInsight, the estimated total diagnosed prevalent amyotrophic lateral sclerosis cases in the 7MM were approximately 500K in 2022. 
• Leading amyotrophic lateral sclerosis companies such as Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others are developing novel amyotrophic lateral sclerosis drugs that can be available in the amyotrophic lateral sclerosis market in the coming years.
• Some of the key therapies for amyotrophic lateral sclerosis treatment include Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), SLS-005 (trehalose), Pridopidine, Masitinib, Tegoprubart (AT-1501), RNS60, Verdiperstat, Zilucoplan, AIT-101 (LAM-002A), and others. 
• In September 2022, the US FDA approved RELYVRIO for ALS. RELYVRIO is a combination of two drugs, sodium phenylbutyrate and taurursodiol, that reduced the rate of decline on a clinical assessment of daily functioning and was associated with longer overall survival
• In May 2022, the oral formulation RADICAVA ORS(edaravone) was approved by the US FDA for treating ALS.

Discover which therapies are expected to grab the major amyotrophic lateral sclerosis market share @ Amyotrophic Lateral Sclerosis Market Report

Amyotrophic Lateral Sclerosis Overview

Amyotrophic lateral sclerosis (ALS), often known as Lou Gehrig’s disease, is a rare neurological disease that primarily affects the nerve cells that control voluntary muscle movement. Voluntary muscles are responsible for motions such as chewing, walking, and talking. The disease is progressive, which means that the symptoms worsen over time. ALS is one of a larger set of conditions known as motor neuron diseases, which are characterized by the progressive degradation and death of motor neurons. Motor neurons are nerve cells that run from the brain to the spinal cord and then to the muscles all over the body.

There is no single test that can offer a definite diagnosis of ALS. ALS is primarily diagnosed based on a detailed history of symptoms and signs noted by a clinician during a physical examination, as well as a battery of tests to rule out other diseases that mimic ALS. The existence of upper and lower motor neuron symptoms, on the other hand, strongly implies the presence of the disease. Electromyography (EMG), nerve conduction study (NCS), and magnetic resonance imaging (MRI) are tests that may aid in the diagnosis of ALS.

Amyotrophic Lateral Sclerosis Epidemiology Segmentation

The amyotrophic lateral sclerosis epidemiology section provides insights into the historical and current amyotrophic lateral sclerosis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The amyotrophic lateral sclerosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Amyotrophic Lateral Sclerosis Prevalence
• Amyotrophic Lateral Sclerosis Diagnosed Prevalence
• Amyotrophic Lateral Sclerosis Gender-Specific Distribution
• Amyotrophic Lateral Sclerosis Mutation-Specific Distribution
• Amyotrophic Lateral Sclerosis Type-specific Distribution
• Amyotrophic Lateral Sclerosis Distribution Based on Site of Onset
• Amyotrophic Lateral Sclerosis Age-specific Distribution

Download the report to understand which factors are driving amyotrophic lateral sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiological Insights

Amyotrophic Lateral Sclerosis Treatment Market 

There is currently no cure for ALS and no effective treatment to slow or stop the disease’s course. Physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy, and other treatments are available in the ALS treatment landscape. Furthermore, the US FDA has approved five medications to treat ALS: RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK. Pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable bursts of sobbing and/or laughing, or other emotional displays) are also treated with medications. Drugs are also available to treat pain, depression, sleep disorders, and constipation. The FDA authorised RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with ALS in September 2022. RELYVRIO (formerly known in the United States as AMX0035). The oral formulation RADICAVA ORS (edaravone) was authorised by the US FDA for the treatment of ALS in May 2022.

Riluzole is indicated as first-line medication for the treatment of ALS in all three regions: Japan, the United States, and Europe. Radicava (Edaravone), a free-radical scavenger, has been licenced for the treatment of ALS. It has the potential to reduce the deterioration in physical function by one-third. Currently, the treatment is only offered in the United States and Japan. Furthermore, NEUDEXTA is approved for the treatment of pseudobulbar effects such as multiple sclerosis and ALS; hence, it is utilised to treat ALS patients. Cramping can be relieved by pain medicines or muscle relaxants such as baclofen (Gablofen, Kemstro, Lioresal) or diazepam (Diastat, Valium).

To know more about amyotrophic lateral sclerosis treatment, visit @ Amyotrophic Lateral Sclerosis Treatment Drugs 

Key Amyotrophic Lateral Sclerosis Therapies and Companies

• Engensis (VM202): Helixmith
• SAR443820/DNL788: Sanofi/Denali Therapeutics
• TPN-101: Transposon Therapeutics
• Latozinemab (AL001/GSK4527223): Alector/GSK
• PrimeC: NeuroSense Therapeutics
• Tofersen (BIIB067): Biogen/Ionis
• ION363: Ionis Pharmaceuticals
• NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
• Reldesemtiv: Cytokinetics/Astellas Pharma
• Pegcetacoplan (APL-2): Apellis Pharmaceuticals
• Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences
• AP-101: AL-S Pharma
• MN-166 (ibudilast): MediciNova
• SLS-005 (trehalose): Seelos Theraputics
• Pridopidine: Prilenia Therapeutics
• Masitinib: AB Science
• Tegoprubart (AT-1501): Eledon Pharmaceuticals
• RNS60: Revalesio Corporation
• Verdiperstat: Biohaven Pharmaceuticals
• Zilucoplan: UCB Pharma/Ra Pharmaceuticals
• AIT-101 (LAM-002A): AI Therapeutics

Learn more about the FDA-approved drugs for amyotrophic lateral sclerosis @ Drugs for Amyotrophic Lateral Sclerosis Treatment 

Amyotrophic Lateral Sclerosis Market Dynamics

The dynamics of the amyotrophic lateral sclerosis market are anticipated to change in the coming years. RADICAVA (edaravone) has proven to be an effective ALS treatment. Recently, oral RADICAVA was licenced in the United States for the treatment of ALS patients in order to improve patient compliance. Most of the 7MM have their own ALS registries, allowing for a near-exact country-wide number of identified and prevalent cases of the disease. Because several ALS-causing mutations have been identified, major parties now have an excellent opportunity to develop drugs that target these variants. 

Furthermore, there is a need for biomarker-specific medications that can help ALS patients enhance their overall health. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the amyotrophic lateral sclerosis market in the 7MM.

However, certain factors may affect the growth of the amyotrophic lateral sclerosis market. The absence of epidemiological data on the disease in the pediatric population stymies the development of innovative medicines aimed at children under the age of 18. ALS is caused by a variety of mutations, many of which have yet to be identified. This research deficit also impedes overall research and development of possible innovative medicines.

Although RADICAVA can effectively delay physical impairment in ALS patients, its expensive price may constitute a threat to overall patient adherence. The approval of novel developing medicines may increase the financial burden on patients. In addition, the failure of current and emerging therapies to entirely cure ALS is a big threat to the amyotrophic lateral sclerosis market.

Scope of the Amyotrophic Lateral Sclerosis Market Report

• Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and emerging therapies
• Amyotrophic Lateral Sclerosis Market Dynamics: Attribute Analysis of Emerging Amyotrophic Lateral Sclerosis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Amyotrophic Lateral Sclerosis Market Access and Reimbursement

Discover more about amyotrophic lateral sclerosis drugs in development @ Amyotrophic Lateral Sclerosis Clinical Trials

Table of Contents

Related Reports

Amyotrophic Lateral Sclerosis Epidemiology Forecast

Amyotrophic Lateral Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted amyotrophic lateral sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Amyotrophic Lateral Sclerosis Pipeline

Amyotrophic Lateral Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key amyotrophic lateral sclerosis companies, including Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, among others.

Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Duchenne muscular dystrophy companies including Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Pfizer, Santhera Pharmaceuticals, ReveraGen BioPharma, Taiho Pharmaceutical, FibroGen, Capricor, Daiichi Sankyo, Italfarmaco, Antisense Therapeutics, Solid Biosciences, among others.

Nonsense Mutation Duchenne Muscular Dystrophy Pipeline

Nonsense Mutation Duchenne Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonsense mutation Duchenne muscular dystrophy companies, including Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, among others.

Becker Muscular Dystrophy Pipeline

Becker Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key becker muscular dystrophy companies, including Italfarmaco, Immunoforge Co., Ltd., Edgewise Therapeutics, Epirium Bio, Ultragenyx, Strykagen, among others.

Facioscapulohumeral Muscular Dystrophy PIpeline

Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key facioscapulohumeral muscular dystrophy companies, including Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc, Avidity Biosciences, Inc., among others.

Other Trending Reports

Actinic Keratosis Market | Acute Coronary Syndrome Market | Acute Pulmonary Embolism Market | Alpha Antitrypsin Market | Apraxia Market | Bile Duct Neoplasm Market | Choroidal Neovascularization Market | Eczema Market | Familial Primary Pulmonary Hypertension Market | Fibrocystic Breast Condition Market | Meningioma Market | Neuroblastoma Market | Opioid Induced Constipation Market | Progressive Multifocal Leukoencephalopathy Market | Rhino Conjunctivitis Market | Ventilator Market | Angioedema Market | Hereditary Angioedema Market | Allergic Conjunctivitis Market | Blood Gas And Electrolyte Analyzers Market | Capnography Device Market | Cervical Intraepithelial Neoplasia Market | Food Allergy Market | Foot And Ankle Devices Market | Intracranial Pressure Monitoring Devices Market | Neurostimulation Devices Market | Neurovascular Devices Market | Osteoarthritis Market | Vascular Access Devices Market | Pruritus Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter